Cancer Treatment

Reference Number: RDF1937-23
Date of Response: 02/11/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1st April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Dear Royal Devon University Healthcare NHS Foundation Trust,

I would be very grateful if you could please answer these questions in relation to cancer treatment.

1) *Over the last 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:*
   (In this context adjuvant melanoma is referring to secondary melanoma tumour treated using the combination of Dabrafenib and Trametinib.)
   Answer: Please see response below; based on the latest SACT data 01/02/2023 to 31/07/2023.

a.	*Metastatic Melanoma*	16
b.	*Adjuvant Melanoma*	*16
c.	*BRAF mutated Lung Cancer*	≤5

*Please note that the Trust's coded reports consider 'adjuvant melanoma' as another term for 'metastatic melanoma'.

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

2) *Over the last 6 months, how many patients were treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:*
   Answer: Please see response below.

a.	*Metastatic Melanoma*	≤5
b.	*Colorectal Cancer*	Nil
c.	*Any other indications*	Nil